Study of the Combination of KD019 and Trastuzumab in Subjects With HER2-Positive Metastatic Breast Cancer
Clinical trial NCT02154529 · TERMINATED
Trial details
- NCT number
- NCT02154529
- Sponsor
- Kadmon Corporation, LLC
- Status
- TERMINATED
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2014-05-01
- Primary completion
- 2015-09-13
- Enrollment
- 17
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.